title: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
abstract: BACKGROUND
  Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.
  
  
  METHODS
  Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28-day schedule at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles.
  
  
  RESULTS
  Of the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4-22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted.
  
  
  CONCLUSIONS
  The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed.
authors.affiliation: Institute of Hematology and Medical Oncology "Seragnoli," University of Bologna, Bologna, Italy.
authors.forename: Enrica
authors.initials: E
authors.lastname: Marchi
authors.forename: Lapo
authors.initials: L
authors.lastname: Alinari
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Nicola
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: Emilio
authors.initials: E
authors.lastname: Berti
authors.forename: Livio
authors.initials: L
authors.lastname: Pagano
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Bernengo
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Serena
authors.initials: S
authors.lastname: Rupoli
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine